Project Grant R43HL186938
Award Date 8/1/26
Completion Date 4/30/27
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arlington, VA 22203, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded the University of South Carolina $100,228 on December 31, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the mechanistic pathways linking hypertension, autoimmunity, and chronic psychological stress. The research tests whether chronic stress exacerbates immune system activation and hypertension in a female hypertensive mouse model of systemic lupus erythematosus (NZBWF1). The investigator's...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Indiana University Indianapolis a Project Grant of $169,444.00 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 5, 2025, with completion targeted for August 31, 2030. This award supports the co-development and pilot testing of a stress management intervention designed specifically for Black adults with elevated blood pressure and hypertension. The research addresses...
- The National Heart, Lung, and Blood Institute awarded Texas A&M University System Health Science Center $758,499 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate a novel beta-adrenergic signaling mechanism that drives interleukin 17A (IL-17A) production and hypertension during chronic stress. The research examines how repeated social defeat stress exacerbates blood pressure rise induced by angiotensin II through IL-17A overproduction by...
- The National Heart Lung and Blood Institute awarded Nusirt Sciences, Inc. $2,095,691 on September 15, 2025, to conduct clinical validation of NS-0200, a fixed combination drug product for the treatment of hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). Work is performed in West Virginia. The period of performance runs through June 30, 2027. The award is structured as a Project Grant, an assistance type commonly used for small business innovation research in the...
- The National Heart Lung and Blood Institute awarded the University of Pittsburgh $1,019,556 on July 13, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a randomized clinical trial testing an adaptive mobile health blood pressure intervention for hypertension management in limited-resource primary care settings. The trial, titled "The Hypertension Toolkit: An Adaptive Mobile Health Blood Pressure Intervention," enrolls 378 participants across...